FMA
LFCR icon

FNY Managed Accounts’s Lifecore Biomedical LFCR Stock Holding History

FNY Managed Accounts’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,000
Closed -$107K – 165
2016
Q3 		$107K Buy
+8,000
New +$96.9K 0.09% 136

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FNY Managed Accounts's LFCR Position: Q4 2016 in Review

FNY Managed Accounts sold out of Lifecore Biomedical (LFCR) in Q4 2016, closing a stake of 8,000 shares — an estimated $107K sold.

FNY Managed Accounts first reported a position in LFCR in Q3 2016 and held it in 1 quarter. The position peaked at $107K in Q3 2016. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2016.

  • FNY Managed Accounts reported no remaining Lifecore Biomedical position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 8,000 Lifecore Biomedical shares in Q4 2016, an estimated $107K.
  • FNY Managed Accounts first reported a position in Lifecore Biomedical in Q3 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Lifecore Biomedical position peaked at $107K in Q3 2016.
  • 93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.